Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on January 20, 2011, reporting events occurring on January 19, 2011. The filing details a strategic partnership and capital raise with Teva Pharmaceutical Industries Limited to support the development of RX-3117, a pre-clinical stage anti-cancer compound.
Key Financial Metrics and Transaction Details
- Capital Raised: $3.95 million from Teva Pharmaceutical Industries Limited.
- Shares Issued: 2,334,515 shares of common stock.
- Price Per Share: $1.682 (calculated as 120% of the closing price on January 5, 2011).
- Transaction Type: Private offering to an accredited investor under Section 4(2) of the Securities Act of 1933.
- Use of Proceeds: Funding the pre-clinical research and development program for RX-3117 and conducting a Phase 0 exploratory clinical study.
Material Changes and Agreements
The company entered into two key amendments on January 19, 2011:
- Second Amendment to Securities Purchase Agreement: Adjusted the aggregate purchase price for Teva's second investment to cover estimated pre-clinical R&D costs plus $450,000 in expenses. It also established a potential third investment option of $750,000 contingent on the satisfactory completion of a Phase 0 study approved by Teva.
- First Amendment to RELO Agreement: Clarified that the Phase 0 study for RX-3117 does not constitute an Investigational New Drug (IND) application and will not trigger milestone payments under the existing Research and Exclusive License Option Agreement.
Outlook, Risks, and Management Commentary
Management believes the proceeds from the $3.95 million investment are sufficient to develop the RX-3117 compound and conduct the Phase 0 study. Teva retains the option to obtain an exclusive, worldwide license for RX-3117 until 45 days after the issuance of an IND application. The filing notes that Teva was granted piggyback registration rights for the shares purchased.
Key Facts for Investor Verification
- Verify the specific estimated costs for the pre-clinical R&D program included in the Second Amendment.
- Confirm the protocols and location for the Phase 0 study as approved by Teva.
- Monitor the timeline for the potential $750,000 third investment contingent on Phase 0 study completion.
- Review the full text of the amended RELO Agreement to understand the specific terms of Teva's exclusive license option.